Fludarabine combination regimen severely affected peripheral blood stem cell mobilization.
Laszlo
Daniele
D
Department of Hematoncology, European Institute of Oncology, Milan, Italy. d_laszlo_2000@yahoo.it
Galieni
Piero
P
Raspadori
Donatella
D
Tozzi
Monica
M
Lauria
Francesco
F
Martinelli
Giovanni
G
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D006085:Graft Survival / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects; D019650:Hematopoietic Stem Cell Mobilization / Q000592:standards*; D006801:Humans; D007700:Kinetics; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods / Q000592:standards; D014182:Transplantation, Autologous; D014740:Vidarabine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology
D018952:Antigens, CD34; D014740:Vidarabine; C024352:fludarabine